Duffy null status predicts severe neutropenia after ciltacabtagene autoleucel but not other BCMA therapies in myeloma

Blood Immunology & Cellular Therapy · Elsevier

The publisher did not provide an abstract — full text is available via the link below.

Read at publisher →

Similar articles